CRIS Cancer Foundation

18/06/2026

On World Kidney Cancer Day, we’re sharing the story of Mark Kellaway, a kidney cancer survivor who was able to start immunotherapy soon after his diagnosis and went on to achieve a full response within a year, with all signs of cancer disappearing.

Stories like Mark’s help to show what progress in cancer care can mean for patients and their families. Behind every advance in treatment are years of research, driven by the dedication of scientists, clinicians, patients and supporters, all working towards better outcomes and more options for people affected by cancer.

At CRIS Cancer Foundation, we support and fund cancer research in the UK and internationally, helping to drive the discoveries that make this progress possible. As we mark 15 years of CRIS Cancer Foundation, we remain committed to supporting the people and research behind advances in cancer care, with the aim of improving outcomes for patients today and in the future.

Watch the full video on our YouTube channel to learn more about the research and the people helping to make progress like this possible. You can find the link below, or visit our bio. https://www.youtube.com/watch?v=QskNru4UUAY

16/06/2026

We are delighted to congratulate Dr Casmir Turnquist, one of our CRIS Cancer Foundation Oxford Fellows at the University of Oxford, on being awarded an NIHR Academic Clinical Lectureship.

This highly competitive award is a wonderful recognition of Dr Turnquist’s potential as a clinician-researcher and marks an important next step in her career. By having dedicated time for research alongside clinical training, it will enable her to further develop her work while continuing to care for patients.

Dr Turnquist’s work focuses on cancers affecting children, adolescents and young adults. Through advanced genomic approaches, her research aims to improve how genetic alterations are identified and understood, helping to support more accurate diagnoses and more informed treatment decisions for young patients.

We are especially pleased that this new award will allow the support already provided through Dr Turnquist’s CRIS Cancer Fellowship to go even further. It is a strong example of how investing in talented researchers at pivotal stages of their careers can help them build momentum, secure further competitive funding, and continue advancing research with the potential to improve outcomes for patients.

Congratulations, Dr Turnquist, on this well-deserved achievement. We look forward to following the next stage of your research journey and the impact of your work in the years ahead.

14/06/2026

Progress in cancer research depends on collaboration, and international partnerships play a vital role in driving discoveries and improving outcomes for patients.

Focusing on prostate cancer, CRIS Cancer works alongside leading organisations and institutions, including the Prostate Cancer Foundation in the United States, to support innovative research and strengthen global scientific networks.

In the UK, CRIS Cancer also partners with Prostate Cancer UK (PCUK), an independent charity. In 2025, for the first time, this collaboration co-funded two fellows: Dr Jacky Leung (The Institute of Cancer Research) and Dr Niamh McKerr (Queen's University Belfast).

Investing in the next generation of researchers is a key part of this commitment, ensuring early career scientists have opportunities to collaborate, grow and make meaningful contributions at a crucial stage in their careers.

In this video, Dr Jacky Leung and Dr Niamh McKerr share their perspectives on the importance of international collaboration and the opportunities it creates through initiatives such as the Career Acceleration Programme.

11/06/2026

International Prostate Cancer Day 🧬

Prostate cancer is one of the most common tumours in men and, although many patients initially respond well to treatment, some tumours gradually adapt and eventually become resistant to therapy. Understanding how this transition happens is essential to improving outcomes for patients.

Dr Dimitrios Doultsinos, based at the University of Oxford , is leading a CRIS Cancer-funded project focused on IRE1, a key regulator of cellular stress that helps tumour cells survive under pressure. His work explores how changes in IRE1 activity may drive the progression towards more aggressive and treatment-resistant prostate cancer.

Using technologies such as single-cell analysis, 3D organoid models and patient-derived samples, the project aims to identify molecular fingerprints that could help predict how tumours evolve and respond to treatment.

By supporting innovative research like this, CRIS Cancer Foundation is helping bring more precise and effective treatments closer to patients. 🔬

10/06/2026

🔔 One for the books at the LSEG

Yesterday, we had the honour of closing trading at the London Stock Exchange .plc, a moment that reflects how far this mission has come and the growing impact of cancer research driven by patients, researchers and supporters working together.

For CRIS Cancer co-founder Lola Manterola, the moment was especially meaningful. After being diagnosed with multiple myeloma in 2008 and receiving life-saving treatment through a clinical trial, Lola co-founded CRIS Cancer Foundation with a clear goal: to support pioneering cancer research and help bring new treatments closer to patients.

What started as a small organisation has grown into an international foundation supporting cutting-edge research, researchers and clinical innovation across the UK, Europe and beyond.

In the United Kingdom, CRIS Cancer Foundation proudly supports pioneering initiatives at The University of Oxford, The Institute of Cancer Research,
Great Ormond Street Hospital and UCL, helping accelerate advances in immunotherapy, cancer prevention and precision medicine, including projects such as LungVax and the Centre for Immunotherapy of Cancer (CIC).

Yesterday’s ceremony was not only a recognition of CRIS Cancer Foundation’s growing international impact, but also a celebration of every researcher, clinician, patient, supporter and partner who has been part of this journey.

🌍 Thank you to everyone who continues to believe in the power of research and innovation to transform cancer outcomes worldwide.

08/06/2026

🧠 8 June is Brain Tumour Day, a global initiative to raise awareness of brain tumours and the need for better treatments.

Although brain tumours are relatively rare in children, they are the second most common type of childhood cancer and the leading solid tumour malignancy. Despite this, they remain significantly under‑researched.

In particular, diffuse midline glioma (DMG) is one of the most aggressive childhood brain tumours. Most children do not survive beyond one year of diagnosis and there is currently no effective treatment available anywhere in the world.

At CRIS Cancer, we are working to change this reality by funding 21 lines of research into childhood brain cancer across our centres in the UK, Spain and France.

Dr Karin Straathof (UCL & Great Ormond Street Hospital and Charity) is leading the first CAR‑T clinical trial in Europe targeting this tumour. Her work uses each patient’s own immune cells, engineered to recognise and destroy cancer cells by targeting a marker found almost exclusively on these tumour cells.

🔬 The knowledge generated through this trial may help lay the foundation for new treatment approaches in the future.

07/06/2026

❤️ Today is National Cancer Survivors Day ❤️

We're proud to share the story of Lola Cavanilles (), a cancer survivor whose journey reflects resilience, perspective and the impact of research.

Seven years ago, Lola was diagnosed with breast cancer, just months after the birth of her fourth child. Looking back, she says: "It made me realise how precious time is and gave me the courage to pursue the passions I had always kept in the background."

Following her recovery, Lola founded Loula Designs, dedicating herself to art, interior design and floral design.

Her story is also a reminder of why cancer research matters. As Lola explains, "the treatments that allowed me to see my children grow up, rebuild my life and pursue my dreams exist because researchers, doctors and patients came before me."

With multiple generations of her family affected by an inherited genetic mutation, and her father currently living with pancreatic cancer, support for research is deeply personal.

At CRIS Cancer, we're committed to funding research that turns progress into hope for patients and families.

Thank you, Lola, for sharing your story and supporting CRIS Cancer. ❤️🔬

28/05/2026

From London to Santiago de Compostela, 1,700 km over 11 days, all driven by purpose 🚴‍♂️

Today we want to celebrate Enrique Alvarez Labiano, who has just completed the Camino challenge, turning a long-distance ride into an incredible opportunity to raise funds to support cancer research.

After losing his uncle Javier to an aggressive brain tumour, Enrique made a promise to keep fighting in his own way: "While he was fighting cancer, I promised him we would fight together, in very different ways."

Enrique has honoured that promise, progressing from six Major Marathons to an even more ambitious challenge this year. He explains: "I admire CRIS Cancer's work in supporting cutting-edge research in cancer, which is why I decided to fundraise for them through my 2026 Camino challenge."

There are many ways to support cancer research, from taking on personal challenges like Enrique’s to helping fund new breakthroughs.

Support Enrique’s fundraising for cancer research here: https://gofund.me/d49f508fa

Thank you, Enrique, for taking action. Thank you for going the distance 💙

20/05/2026

Today is National Clinical Trials Day 🔬, a day to honour the patients who take part in clinical trials and the professionals advancing medical research, and we want to celebrate three of the incredible researchers we fund at CRIS Cancer Foundation.

Behind every clinical trial is years of work, rigorous testing, and patients who are counting on science to find a way forward. Over the past 15 years, we have supported 736 clinical trials, helping bring new treatment options closer to reality.

These three researchers are doing exactly that, for children with brain tumours, lung cancer survivors, and families facing leukaemia with nowhere else to turn.

Swipe to meet them 👉

1️⃣ Professor Persis Amrolia | Great Ormond Street Hospital and Charity

CAR-T therapy has given children with leukaemia a fighting chance, but for half of those who relapse, that chance runs out within a year. Current therapies rely on a single target on the surface of cancer cells, and when the cancer learns to mask it, treatment stops working. The immune cells can also become overstimulated and burn out before they have finished the job.

Professor Amrolia's trial addresses both problems, using engineered immune cells that can recognise cancer in two different ways and are designed to keep working for longer.

2️⃣ Professor Sarah Blagden | University of Oxford

Most cancer vaccines have focused on treatment, but Professor Blagden's trial is focused on prevention. Using the same platform as the Oxford COVID vaccine, her team is training the immune system to recognise and respond to the mutations that drive lung cancer, before it has the chance to return.

After analysing tumour samples from 8,000 patients, they designed a vaccine with the potential to cover 96% of this cancer type and it will target early-stage lung cancer survivors and people at high risk.

3️⃣ Dr Karin Straathof | UCL & Great Ormond Street Hospital and Charity

Diffuse midline glioma is a brain cancer that takes most children within a year of diagnosis, and there is currently no effective treatment anywhere in the world.

Dr Straathof is leading the first CAR-T trial in Europe to target this tumour, taking immune cells from each patient and engineering them to identify and destroy the cancer using a marker found almost exclusively on these tumour cells. The knowledge being gathered through this trial could help lay the foundation for entirely new treatments in the future.

14/03/2026

The work of Professor Alan Melcher and his team at The Institute of Cancer Research (London), supported by CRIS Cancer Foundation since 2021, has been selected to participate in a major Horizon Europe research programme with €8 million in funding.

This support will enable the OCTOPOD-IV Phase 2 clinical trial, an international study evaluating a next-generation oncolytic immunotherapy designed to destroy cancer cells and activate the immune system in patients with platinum-resistant ovarian cancer—an aggressive disease with very limited treatment options.

The project brings together several world-leading research centres, including The Institute of Cancer Research(London, UK, Clínica Universidad de Navarra (Spain), Catalan Institute of Oncology (Spain), The Princess Margaret Cancer Foundation (Toronto, Canada)

This international collaboration represents an important step forward in developing new therapeutic strategies for patients with this challenging disease.

16/03/2024

01/02/2019

New video! New remixes!
\ GINEVRA ft. Dsordne - STONER Ep /
out now

https://triplevoidrecords.bandcamp.com/album/ginevra-ft-dsordne-stoner-ep

From DEATH BY STROBE album (Triple Void Records) http://www.triplevoidrecords.com Directed by Mario Toyoshima http://www.ginevrawords.com http://www.facebook...

30/01/2019

01 . 02 . 2019
GINEVRA ft. Dsordne - Stoner EP
1. Stoner
2. Stoner (DsorDNE remix)
3. Stoner (Angel Heart remix)
4. New Videoclip from Sacrosanto Manifesto
https://triplevoidrecords.bandcamp.com and everywhere...

09/10/2018

'Ginevra - Death By Strobe' album is now available on sale on CD digipak (300 limited edition) on our Bandcamp page:

8 track album

04/10/2018

GINEVRA's Dismay on XRAY.FM!

60 minutes dedicated to post-punk, darkwave, cold wave, Neue Deutshe Welle and whatever other signifiers, with perhaps the strongest emphasis on the local post-punk scene of any radio show in the Portland area. From the first wave to NOW, it's here.

13/06/2018

C’è un ritmo per ballare, uno per pensare, un altro ancora per attraversare il confine che sta tra la luce e l’ombra. Per inseguire pensieri inquieti, per lasciarsi tentare dalle domande. Quelle che, spesso, non trovano risposta. Eppure, a volte, la musica riesce a compiere un piccolo incantesi...

08/05/2018

New review of DEATH BY STROBE // ROCKERILLA magazine #453 //May 2018

04/05/2018

\\ GINEVRA - DEATH BY STROBE //
\\ NEW ALBUM OUT NOW //
https://triplevoidrecords.bandcamp.com/album/ginevra-death-by-strobe-tvr002

28/03/2018

NEWS NEWS NEWS
GINEVRA's debut album 'Death By Strobe' has a release date: 04 MAY 2018.

/ No.100 Limited Edition 12" Vinyl
/ Digital stores
/ Triple Void Records Bandcamp

Tracklist
DEATH BY STROBE
- Clairvoyance
- Dismay
- Lloyd
- 3891
- Spiral
- Stoner
- Never
- Death By Strobe

01/02/2018

Dsordne - Exexex_Remix Himself (TVR001)
Limited Edition CD
Coming Soon